MARSEILLE, France & DIAMOND BAR, Calif.–(BUSINESS WIRE)–Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA), together with the Institute for Follicular Lymphoma) today announced that they have entered into an agreement to clinically study the potential of IPH6501, Innate’s anti-CD20 ANKET in follicular lymphoma (FL).
Innate’s ongoing Phase 1/2, open-label, multicenter trial investigating the safety, tolerability, and preliminary antineoplastic activity of IPH6501 in patients with relapsed and/or refractory CD20-expressing Non-Hodgkin Lymphoma will also include patients with relapsed / refractory (R/R) FL.
To support the Phase 1/2 trial and inclusion of FL patients, IFLI will initially invest 3m USD into new shares of Innate, issued through a capital increase reserved to IFLI at a price of €1.56 per share and representing 2.26% of the share capital of Innate.
IFLI may also invest up to an additional 4.9m USD into new shares of Innate, depending on the completion of certain milestones, at a price to be determined at the time of the said investments.
“At Innate Pharma, we are deeply committed to advancing innovative research and development to improve outcomes for patients with non-Hodgkin lymphoma and this agreement with the Institute for Follicular Lymphoma Innovation will contribute to our mission to bring forward therapeutic options that address critical needs and enhance the quality of life for those affected by this challenging disease,” said Dr Sonia Quaratino, Chief Medical Officer of Innate Pharma.
“IFLI believes IPH6501 holds great promise for improving patient outcomes in non-Hodgkin lymphomas including follicular lymphoma,” said Dr. Michel Azoulay, Chief Medical Officer of IFLI. “We are delighted to support Innate and the investigation of IPH6501 in FL patients and, upon milestone achievement, to continue to support future clinical development of IPH6501 in FL. This collaboration provides a model for how IFLI’s philanthropic investments can catalyze FL development.”
You can find more details on the transaction in the attached PDF.
About The Institute for Follicular Lymphoma Innovation
The Institute for Follicular Lymphoma Innovation (IFLI) is a global, non-profit, private foundation dedicated to accelerating the development of innovative treatment options for patients with follicular lymphoma (FL). IFLI supports cutting-edge research and technology to lead to the development and commercialization of novel therapeutics and/or biomarkers for the treatment of FL, and to understand the biology of FL. The foundation deploys its budget across grants, project-based partnerships, and venture philanthropic investments to achieve its innovation goals. IFLI promotes collaboration and works to enable data sharing and the exchange of knowledge and expertise among researchers and institutions advancing FL research. Learn more at www.i-fli.org.
About Innate Pharma
Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Its innovative approach aims to harness the innate immune system through therapeutic antibodies and its ANKET® (Antibody-based NK cell Engager Therapeutics) proprietary platform.
Innate’s portfolio includes lead proprietary program lacutamab, developed in advanced form of cutaneous T cell lymphomas and peripheral T cell lymphomas, monalizumab developed with AstraZeneca in non-small cell lung cancer, as well as ANKET® multi-specific NK cell engagers to address multiple tumor types.
Innate Pharma is a trusted partner to biopharmaceutical companies such as Sanofi and AstraZeneca, as well as leading research institutions, to accelerate innovation, research and development for the benefit of patients.
Headquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.
Learn more about Innate Pharma at www.innate-pharma.com and follow us on Twitter and LinkedIn.
